QNASL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for QNASL (QNASL).
Beclomethasone dipropionate is a corticosteroid with anti-inflammatory activity. It binds to glucocorticoid receptors, inhibiting inflammatory mediators such as prostaglandins and leukotrienes, and reducing nasal inflammation.
| Metabolism | Hepatic metabolism via CYP3A4 to active metabolite beclomethasone-17-monopropionate (17-BMP) and other inactive metabolites. |
| Excretion | The majority of a dose (approximately 40-50%) is excreted in feces as unchanged drug and metabolites, with about 10-15% excreted in urine as metabolites. Biliary excretion is the primary route of elimination. |
| Half-life | The terminal elimination half-life is approximately 8-10 hours in healthy adults, supporting twice-daily administration for systemic effects; however, intranasal administration results in minimal systemic absorption, and local half-life in nasal tissues is not well characterized. |
| Protein binding | Beclomethasone dipropionate is 87% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin. |
| Volume of Distribution | The volume of distribution for beclomethasone dipropionate after intravenous administration is approximately 20 L (0.3 L/kg for a 70 kg adult), indicating extensive tissue distribution. |
| Bioavailability | The absolute bioavailability after intranasal administration is less than 1% due to extensive first-pass metabolism in the liver and local degradation; oral bioavailability is also less than 1%. |
| Onset of Action | Improvement in nasal symptoms may be observed within 12 hours after the first intranasal dose, with significant clinical effect typically seen by 24-36 hours. |
| Duration of Action | The therapeutic effect lasts for approximately 24 hours after intranasal administration, allowing once or twice daily dosing; however, consistent use over several days is required for maximal symptom control. |
1 to 2 sprays (80 mcg/spray) per nostril once daily; maximum 2 sprays/nostril/day.
| Dosage form | AEROSOL, METERED |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | For children 12 years and older: same as adult. For children 4-11 years: 1 spray (80 mcg) per nostril once daily. |
| Geriatric use | No specific dose adjustment; use with caution due to potential increased systemic sensitivity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for QNASL (QNASL).
| Breastfeeding | It is unknown whether beclomethasone dipropionate is excreted in human milk after intranasal administration. Other corticosteroids are excreted in breast milk, but systemic exposure after intranasal use is minimal. The M/P ratio is not available. Benefit of breastfeeding should be weighed against potential risk to the infant. |
| Teratogenic Risk | QNASL (beclomethasone dipropionate) is an intranasal corticosteroid. Based on animal studies, corticosteroids have been associated with an increased risk of cleft palate and other fetal malformations at high systemic exposures. However, intranasal administration results in minimal systemic absorption. Available human data from epidemiological studies do not suggest an increased risk of congenital anomalies from intranasal corticosteroids. Therefore, the fetal risk is considered low, but caution is warranted, especially during the first trimester. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to beclomethasone dipropionate or any component of the formulation","Untreated localized nasal infection"]
| Precautions | ["Local nasal effects: epistaxis, nasal ulceration, Candida albicans infection","Hypothalamic-pituitary-adrenal (HPA) axis suppression with higher doses","Slowing of growth in children","Increased susceptibility to infections due to immunosuppression","Ocular effects: glaucoma, cataracts","Hypersensitivity reactions including anaphylaxis","Use caution in patients with tuberculosis, herpes simplex, or other infections"] |
Loading safety data…
| Fetal Monitoring | No specific monitoring is routinely required. As with any corticosteroid use during pregnancy, monitor for signs of adrenal suppression or growth retardation in the fetus if used at high doses or systemically, though this is unlikely with intranasal use. |
| Fertility Effects | In animal studies, beclomethasone dipropionate did not impair fertility at clinically relevant doses. Human data are lacking, but intranasal corticosteroids are not expected to affect fertility due to minimal systemic absorption. |